



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)


PRODUCT INFORMATION



Diquafosol (sodium salt)

Item No. 33971

CAS Registry No.: 211427-08-6
Formal Name: uridine 5'-(pentahydrogen tetraphosphate), P'''→5'-ester with uridine, tetrasodium salt
Synonyms: INS365, KPY 998
MF: C₁₈H₂₂N₄O₂₃P₄ • 4Na
FW: 878.2
Purity: ≥95%
UV/Vis.: λ_{max}: 263 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Diquafosol (sodium salt) is supplied as a solid. Aqueous solutions of diquafosol (sodium salt) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of diquafosol (sodium salt) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Diquafosol is an agonist of purinergic P2Y₂ and P2Y₄ receptors (EC₅₀s = 0.1 and 0.4 μM, respectively, in calcium mobilization assays).¹ It is selective for P2Y₂ and P2Y₄ receptors over P2Y₆ receptors (EC₅₀ = 20 μM). Ocular application of diquafosol (0.1 and 1% w/v) induces the release of mucin-like glycoproteins from rabbit conjunctival goblet cells, as well as reduces desiccation-induced corneal damage in a rabbit model of dry eye disease.² Formulations containing diquafosol have been used in the treatment of dry eye disease.

References

1. Pendergast, W., Yerxa, B.R., Douglass, J.G., III, *et al.* Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. *Bioorg. Med. Chem. Lett.* **11(2)**, 157-160 (2001).
2. Fujihara, T., Murakami, T., Nagano, T., *et al.* INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. *J. Ocul. Pharmacol. Ther.* **18(4)**, 363-370 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/12/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM